Boehringer Ingelheim has acquired University of Basel spinout T3 Pharmaceuticals for 450 million CHF ($507.4 million) in an effort to expand its immuno-oncology portfolio with T3’s platform.
The companies have a prior relationship through the Boehringer Ingelheim Venture Fund, which participated in a 2019 round worth 12 million CHF ($13.5 million). In 2020, T3 raised 25 million CHF ($28.2 million) in its third financing round to fund its lead candidate.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.